Skip to main content
森萱医药 logo

森萱医药 — Investor Relations & Filings

Ticker · 920946 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2023-12-07 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920946

About 森萱医药

https://www.senxuan.cn/

Jiangsu Senxuan Pharmaceutical Co., Ltd. specializes in the research, development, and production of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and specialized fine chemicals. The company’s product portfolio includes key intermediates for antiviral medications, such as those used in the treatment of HIV, and anticonvulsant agents like Primidone. Additionally, it produces high-purity chemical solvents including 1,4-dioxane and 1,3-dioxolane for diverse industrial applications. Senxuan Pharmaceutical maintains a focus on advanced chemical synthesis and large-scale manufacturing capabilities, adhering to international quality standards to support the global life sciences and chemical sectors. Its operations are characterized by a commitment to technical innovation and the supply of critical chemical building blocks for complex therapeutic formulations.

Recent filings

Filing Released Lang Actions
开源证券股份有限公司关于江苏森萱医药股份有限公司变更募集资金用途的核查意见
Regulatory Filings Classification · 85% confidence The document is an inspection opinion (核查意见) provided by the sponsor (开源证券) on Jiangsu Senxuan Pharmaceutical’s proposed change in use of IPO proceeds. It is neither an earnings release nor a financial report (10-K, IR) nor a proxy or AGM material. It does not announce new fundraising or board changes, but rather is a regulatory compliance filing under Beijing Stock Exchange rules. It therefore falls into the fallback category for miscellaneous regulatory announcements: RNS.
2023-12-07 Chinese
关于预计2024年日常性关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Jiangsu Senxuan Pharmaceutical Co., Ltd. regarding the expected related party transactions for the year 2024. It includes detailed information about the types and amounts of transactions expected, descriptions of related parties, their financial data, and the board and committee approvals related to these transactions. The document is not a full financial report but rather a disclosure about anticipated related party transactions, including board meeting resolutions and independent opinions. It does not contain comprehensive financial statements or detailed financial analysis typical of annual or interim reports. It is also not a simple notice of report publication or certification. The content fits best with a regulatory announcement about related party transactions, which is a typical regulatory filing. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (8528 characters) and detailed content support this classification with high confidence.
2023-12-07 Chinese
对外投资公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jiangsu Senxuan Pharmaceutical Co., Ltd. regarding an external investment. It details the company's plan to use raised funds to increase the registered capital of its wholly-owned subsidiary for a specific production project. The document includes information about the investment amount, the subsidiary's financials, the purpose and risks of the investment, and approvals from the board and supervisory committee. There is no indication that this is a full financial report, audit report, or earnings release. It is a corporate announcement about a capital investment activity, specifically an increase in registered capital of a subsidiary using raised funds. This fits the category of Capital/Financing Update (CAP). The document length is under 5,000 characters and contains substantive details about the investment, not just a brief notice or report publication announcement. Therefore, the best classification is CAP with high confidence.
2023-12-07 Chinese
关于选举第四届董事会专门委员会委员的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the election of members to the company's board specialized committees, including the audit committee, strategy committee, nomination committee, and remuneration & assessment committee. It references compliance with company law, stock exchange rules, and governance requirements. There is no financial data, earnings information, or report publication mentioned. The content focuses on board and committee composition and governance matters. Therefore, this fits the category of Board/Management Information (MANG). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS.
2023-12-07 Chinese
第四届董事会第一次会议决议
Board/Management Information Classification · 100% confidence The document is a detailed announcement of resolutions passed at the first meeting of the fourth board of directors of Jiangsu Senxuan Pharmaceutical Co., Ltd. It includes information about the election of board chairman, vice chairman, committee members, and appointments of senior management such as general manager, deputy general manager, board secretary, financial officer, and securities affairs representative. It also covers agenda items related to changes in use of raised funds and expected related party transactions. The document references other announcements for detailed content but itself focuses on board and management changes and decisions. There is no financial data or earnings information, nor is it a report or presentation. The content clearly fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2023-12-07 Chinese
2023年第三次临时股东大会法律意见书
Regulatory Filings Classification · 82% confidence The provided document is a Chinese law firm’s formal legal opinion letter on the convening, holding and voting procedures of Jiangsu Senxuan Pharmaceutical Co., Ltd.’s 2023 third extraordinary shareholders’ meeting. It is not the company’s own meeting notice or proxy solicitation, nor is it an earnings, audit or management report, but rather a compliance/legal opinion submitted to satisfy regulatory requirements. This type of letter does not fit any of the highly specific financial report categories and thus falls into the general regulatory/ compliance filing category.
2023-12-07 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.